09:50 AM EST - Valeant Pharmaceuticals International, Inc : Announced preliminary unaudited financial information for the fourth quarter 2015. Preliminary Highlights include unaudited revenue of $2.8 billion; unaudited GAAP EPS ($0.98); Adjusted EPS (non-GAAP) $2.50; Unaudited GAAP cash flow from Operations $562 million; adjusted cash flow from Operations (non-GAAP) $838 million. Valeant Pharmaceuticals International, Inc
shares T.VRX are trading down $23.30 at $68.28.
